{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:42Z","timestamp":1760028942044},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T00:00:00Z","timestamp":1390953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Statins effectively lower low\u2010density lipoprotein cholesterol (<jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C), reducing cardiovascular morbidity and mortality. Most patients tolerate statins well, but approximately 10% to 20% experience side effects (primarily muscle\u2010related) contributing to diminished compliance or discontinuation of statin therapy and subsequent increase in cardiovascular risk. Statin\u2010intolerant patients require more effective therapies for lowering <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C. Proprotein convertase subtilisin\/kexin type 9 (<jats:styled-content style=\"fixed-case\">PCSK9<\/jats:styled-content>) is a compelling target for <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C\u2013lowering therapy. Evolocumab (<jats:styled-content style=\"fixed-case\">AMG<\/jats:styled-content> 145) is a fully human monoclonal antibody that binds <jats:styled-content style=\"fixed-case\">PCSK9<\/jats:styled-content>, inhibiting its interaction with the <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content> receptor to preserve <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010receptor recycling and reduce <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C. Phase 2 studies have demonstrated the safety, tolerability, and preliminary efficacy of subcutaneous evolocumab in diverse populations, including statin\u2010intolerant patients. This article describes the rationale and design of the Goal Achievement After Utilizing an anti\u2010<jats:styled-content style=\"fixed-case\">PCSK9<\/jats:styled-content> Antibody in Statin\u2010Intolerant Subjects 2 (<jats:styled-content style=\"fixed-case\">GAUSS<\/jats:styled-content>\u20102) trial, a randomized, double\u2010blind, ezetimibe\u2010controlled, multicenter phase 3 study to evaluate the effects of 12\u2009weeks of evolocumab 140\u2009mg every 2\u2009weeks or 420\u2009mg every month in statin\u2010intolerant patients with hypercholesterolemia. Eligible subjects were unable to tolerate effective doses of \u22652 statins because of myalgia, myopathy, myositis, or rhabdomyolysis that resolved with statin discontinuation. The primary objective of the study is to assess the effects of evolocumab on percentage change from baseline in <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C. Secondary objectives include evaluation of safety and tolerability, comparison of the effects of evolocumab vs ezetimibe on absolute change from baseline in <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010C, and percentage changes from baseline in other lipids. Recruitment of approximately 300 subjects was completed in August 2013.<\/jats:p>","DOI":"10.1002\/clc.22248","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T20:30:58Z","timestamp":1391027458000},"page":"131-139","source":"Crossref","is-referenced-by-count":26,"title":["Design and Rationale of the <scp>GAUSS<\/scp>\u20102 Study Trial: A Double\u2010Blind, Ezetimibe\u2010Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (<scp>AMG<\/scp> 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy"],"prefix":"10.1002","volume":"37","author":[{"given":"Leslie","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Colquhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Dent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-005-5686-z"},{"key":"e_1_2_6_4_1","unstructured":"TopolEJ.The diabetes dilemma for statin users.New York TimesMarch 4 2012.http:\/\/www.nytimes.com\/2012\/03\/05\/opinion\/the\u2010diabetes\u2010dilemma\u2010for\u2010statin\u2010users.html?pagewanted=print. Accessed August 26 2013."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2011.05.007"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-7-201304020-00004"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211798220891"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02798-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903849106"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61770-X"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61771-1"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.144055"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.25790"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/ circulationaha.113.007012"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1112023"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/75.4.800"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800091-JLR200"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M700071-JLR200"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M702027200"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.986"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.007"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201832"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105803"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2013.03.083"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.053"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.02.014"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000170913.73780.5f"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30156"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61731-0"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs023"},{"key":"e_1_2_6_34_1","unstructured":"Juxtapid (lomitapide) tablets [US full prescribing information]. Cambridge MA: Aegerion Pharmaceuticals Inc. December 2012. Available at:http:\/\/www.aegerion.com\/Collateral\/Documents\/English\u2010US\/R3_JuxtapidCombinationPI_QC_21Dec12%20pdf%20pdf.pdf. Accessed November 22 2013."},{"key":"e_1_2_6_35_1","unstructured":"Kynamro (mipomersen sodium) injection [US full prescribing information]. Cambridge MA: Genzyme Corporation. January 2013. Available at:http:\/\/www.kynamro.com\/\u223c\/media\/Kynamro\/Files\/KYNAMRO\u2010PI.pdf. Accessed November 22 2013."},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3283612454"},{"key":"e_1_2_6_37_1","unstructured":"US National Institutes of Health ClinicalTrials.gov. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). November 1 2013. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01764633. Accessed November 20 2013."}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22248","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:29:56Z","timestamp":1696314596000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,29]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/clc.22248"],"URL":"https:\/\/doi.org\/10.1002\/clc.22248","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,29]]}}}